Get started
MODERNA INCMODERNA INCMODERNA INC

MODERNA INC

No trades
See on Supercharts
Overview Financials News
Ideas
Discussions Technicals Forecast Seasonals

0QF trade ideas

What May Happen to Moderna and Pfizer?International pharmaceutical giant Merck & Co announced the successful end of its clinical trial of the world’s first oral COVID-19 antiviral drug molnupiravir in the simple form of a pill. The company has claimed that molnupiravir effectively decreases the risk of hospitalization and death of sick individuals who have just contracted the virus or have advanced symptoms by half.  Moreover, the company also suggested that molnupiravir could be used to prevent the contraction of  the coronavirus. But what is most important at this stage is that fact that the clinical trials of molnupiravir showed high effectiveness against different COVID-19 variants, including the terrifying Delta variant. This seems to be good news for antivaxers or for anybody who is looking for an alternative prevention method from COVID-19 other than the vaccine.  Whether you agree or disagree with having the vaccine, it is worthwhile to consider this information as a means of expanding your investment portfolio with Merck stocks. Additionally, COVID-19 major vaccine producers Pfizer and Moderna stocks may suffer if the new pill is officially registered. Let’s take a look at Pfizer and Moderna’s price charts. Both stocks suffered a 50% correction from their peaks in August. Although, Pfizer business model is more diversified than that of Moderna’s, the technical picture shows that the upward trend for Pfizer stocks is more in danger. The reason for such fears is that over the last three consecutive trading sessions its stocks closed below the trend support line that started in February 2021. So, if Pfizer stock prices fail to recover above the $43.20-44 correction, they are likely to continue towards the $38.20-39.20 area. In this area, two important technical lines cross – one is the support line of the upward trend that started in March 2020 and the second – former resistance line that connects September 2020 and May, June 2021 highs. Pfizer and BioNTEch may have a trump of positive opinion by the Committee for Medicinal Products for Human Use (CHMP) for the administration of the Pfizer-BioNTech COVID-19 vaccine as a booster shot six months after the second dose, but this factor is already priced in. The Moderna stock prices chart seems to be more complex as it shows that the March 2020 long-term upward trend is supported by the upward trend that started in May 2021 in the area of $319-321. Even the correction from the peak of $496.71 closely echoes the ABC correction structure, where A and C waves are equal. And if so, Moderna stocks may recover both not only to recent highs, but to new all-time highs. Such a scenario might be activated if prices hold above the downward channel from August 10. In this case new targets may open at $563-565. Technical perspectives of Merck stocks will be reviewed in the coming comments.
NASDAQ:MRNALong
by scavoanastasiia
4
MRNA (MODERNA) - False BreakMarket structure: Uptrend, price might retest previous resistance turn support Setup: False Break/ Retest previous resistance turn support False Break candlestick pattern: Hammer / Bullish engulfing To look for trading opportunities when price retest previous resistance turn support at around 361.00 area. Stop loss: 1 ATR stop loss taking reference from the retest Take profit: Swing High around 484.30 area Disclaimer: Below simple trading idea is just for sharing, please do your own due diligence and apply risk management.
NASDAQ:MRNALong
by AhKeongTheTrader
3
MRNA10.3.21 MRNA Bobby's Homework Assignment : MRNA is likely to find buyers in this general area. We missed the buying tail... but this is not a big deal. This was a difficult video for reasons that I explain in the video. It is very important to start using the drawing tools to get familiarity and learn the process of using those tools to read the market. Use the honeymoon period to get familiar with the tools. The honeymoon period is exciting, and you expect that there will be a learning curve, but your excitement can give you motivation. You expect the tools to be unfamiliar in the beginning, but if you tackle that aspect of your trading, it won't seem so bad with 30 days of effort. On the other hand, if you don't use that period of time with enthusiasm you may never achieve your goal.
NASDAQ:MRNA
by ScottBogatin
1
MODERNA POSSIBLE DISTRIBUTION!Hello my beauties. I think MRNA has entered a distribution range, as the ST (second test) seemed to be pretty weak, and the price is now showing weakness below the trading range. We are going to wait for further developments in price action and eventually take a trade on the final LPSY. For those of you who like trading ranges, this might be a juicy opportunity. Watch for the creation of an UT (upthrust) and an UTAD (upthrust after distribution) before you take your trade. If you find this idea to be helpful like, follow, and drop a comment below if you'd want me to analyse a different pair. Consider supporting me if you think I am providing you with value. Peace. Luca, TrickleDownFX
NASDAQ:MRNAShort
by TrickleDownFX
3
Expect Breakdown in MRNAI've been thinking about this one and all the hype around it and guessing it's time to retrace. It broke it's first uptrend line today on a daily chart and the parabolic SAR turned bearish. I checked with my dowsing work and was given the "breakdown" option literally 3 xs. When that kinda stuff happens, I like to pay attention. Ex. Friday and today I kept getting the "parabolic" option and you can see how that turned out. :) I also got "breakdown" before AMZN earnings for reference. I'm looking for a target around $330.
NASDAQ:MRNAShort
by JenRz
MRNA9.30.21 MRNA Bobby's Homework Assignment Part 2 Take 2: technical error on last video....sorry about that....no big deal. This is my general plan: I am at year two of doing this, and I'm getting tired of teaching the tools because new people come along and they didn't listen to the videos that explain the tools in the past.So I decided the title a series of these videos as Bobby's homework assignment so that people who come along in the future can go to Bobby's homework assignments that show you how to set up the tools… So that I never have to do this again. This way, I can talk more efficiently about expansion and contraction, and certain other properties of the market that are a little bit more elusive to people who are used to looking at the market a certain way. I'm trying to decide how extensive I want to make this series of videos. The fact is Bobby needs to learn about commodity markets even though his teacher is not interested in this. In his economics class they are talking about risk versus reward and low yielding markets that have lower risk, but are considered safer. So in the class they will talk about bonds, or treasury notes as safer vehicles with less risk. What this economics class will never get into because it is beyond the scope of an economics class... Is how to use some of these futures markets where the risk is thought to be higher because of the way those markets are leveraged, but if you know how to deal with this, you have a much higher chance of being substantially more profitable with less real risk if you know how to trade. For example if Bobby has an imaginary account of $1 million, Bobby can trade many contract or large contract of oil and target profits and identify risk and with one or two contracts every now and then in just oil alone, his risk of rolling is almost 0 because a traitor who has $1 million of assets can trade an oil contract or a gold contract, and if in doubt a mini contract and make a huge difference in his return. This paragraph is a long paragraph and 90% of the people won't read it. And that's okay. I'm hoping that Bobby reads and does the work on his homework assignments and then he will learn things that will never tell him in economics class, but he will learn it in his lifetime the hard way or the easy way. It's very hard to make substantial profit with no risk, but it is very hard to maintain your purchase power because of the devaluation of currencies when your major goal is to avoid risk.
NASDAQ:MRNA
by ScottBogatin